Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04879043 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Plasma Cell Disorder, sponsored by Heidelberg Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 16
- Study locations
NCT04879043: Recruiting Phase 1 study of Multiple Myeloma and Plasma Cell Disorder, sponsored by Heidelberg Pharma.
NCT04879043 is a Phase 1 study of Multiple Myeloma and Plasma Cell Disorder that is actively recruiting participants, run by Heidelberg Pharma. The registered enrollment target is 78 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (86% lower). The trial reports 16 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04879043, a Phase 1 study of Multiple Myeloma and Plasma Cell Disorder, is actively recruiting participants, sponsored by Heidelberg Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Conditions Studied
Interventions
- DRUG HDP-101
Study Locations (16)
Other
- Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie - Berlin
- Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III - Chemnitz
- Universitätsklinikum Köln - Cologne
- Asklepios Klinik Altona, Haematologie und internistische Onkologie - Hamburg
- Universitätsklinikum Heidelberg - Heidelberg
- Universitätsklinikum Schleswig-Holstein - Kiel
- UKSH Campus Lübeck Klinik für Hämatologie und Onkologie - Lübeck
- Universitätsklinikum Mainz - Mainz
- Semmelweis University, Belgyogyaszati es Onkologiai Klinika - Budapest
- National Institute of Oncology, Department of Oncological Internal Medicine - Budapest
- Pratia Onkologia Katowice - Katowice
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi - Lodz
- Szpital Wojewodzki w Opolu - Opole
Georgia
- Winship Cancer Institute of Emory University - Atlanta
New York
- Mount Sinai, The Tisch Cancer Instutute - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What NCT04879043 shows while recruiting
NCT04879043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which HDP-101 is the first listed.
NCT04879043 lists 16 locations in 4 states (Other, Georgia, New York).
Frequently Asked Questions
What is clinical trial NCT04879043 about?
NCT04879043 is a clinical study titled "Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma". This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
What is the current status of trial NCT04879043?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2022-02-07. Estimated completion is 2026-05.
What conditions does trial NCT04879043 study?
This clinical trial studies the following conditions: Multiple Myeloma, Plasma Cell Disorder.
What interventions are being tested in trial NCT04879043?
The interventions under investigation include: HDP-101 (DRUG).
Who is sponsoring clinical trial NCT04879043?
This trial is sponsored by Heidelberg Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04879043 being conducted?
This trial has 16 study locations across Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04879043's enrollment target sits among peer trials
78 204th of 438 higher than 234 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI